U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices Guidance for Industry and Food and Drug Administration Staff September 2022

Final
Docket Number:
FDA-2014-D-0798
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

FDA is issuing this guidance to communicate how the Agency intends to apply its regulatory oversight to medical device data systems (MDDS), medical image storage devices, and medical image communication devices. FDA does not intend to enforce the requirements of the Federal Food, Drug, and Cosmetic Act for hardware functions that are considered to be MDDS, medical image storage devices, or medical image communication devices, provided that the hardware function is limited to assisting the following software functions: electronic transfer, storage, conversion of formats, or display of medical device data and results. Software functions that are solely intended to transfer, store, convert formats, or display medical device data and results, including medical images, waveforms, signals, or other clinical information, are not devices and are not subject to applicable FDA regulatory requirements.

This guidance was revised through a minor update to reflect amended medical device classification regulations following the issuance of the final rule, “Medical Devices; Medical Device Classification Regulations To Conform to Medical Software Provisions in the 21st Century Cures Act” (86 FR 20278). 


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-0798.

Back to Top